Divi's Laboratories Ltd. News and Updates

Name: Latest research reports of Divi's Laboratories Ltd. authored by Geojit BNP Paribas and published by - Trendlyne research reports.
Item: Divi's Laboratories Ltd.
Rating: 3
Author: Geojit BNP Paribas

Keep track of all breaking news on Divi's Laboratories Ltd. from all sources in a single place.

Divi's Laboratories Ltd.

25 Mar 2025

5734.50

2.60%

DIVI' S LAB

Hold: Divi's Laboratories Ltd.

Target

Geojit BNP Paribas

Number of FII/FPI investors increased from 723 to 826 in Dec 2024 qtr.

Divi's Laboratories Ltd.

05 Feb 2025

5734.50

2.60%

High value projects will sustain growth in Custom Synthesis segment

Accumulate: Divi's Laboratories Ltd.

Target

KRChoksey

DIVISLAB revenue beat our estimates (+3.9%) due to strong growth in Custom Synthesis segment. EBITDA beat our estimates due to better-than-expected gross profit and lower than expected employee expenses. Adj. PAT was beat due to lower-than-expected effective tax rate.

Divi's Laboratories Ltd. has gained 51.72% in the last 1 Year

Divi's Laboratories Ltd.

04 Feb 2025

5734.50

2.60%

DIVI'S LABORATORIES

Accumulate: Divi's Laboratories Ltd.

Recommendation Target

Prabhudas Lilladhar

Divi's Laboratories Ltd. is trading above its 200 day SMA of 5529.0

Divi's Laboratories Ltd.

03 Feb 2025

5734.50

2.60%

Divi's Laboratories Results Earnings Call for Q3FY25

Conference Call with Divi's Laboratories Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.

Divi's Laboratories Ltd.

03 Feb 2025

5734.50

2.60%

Divis Labs share surge 5% after profits rise 64% in Q3 results; know more

Business Standard

Divi's Laboratories share price slipped 4.60 per cent at Rs 5,881.15 a piece on the BSE in Monday's intraday trade after the pharmaceutical company's consolidated net profit for the third quarter

Divi's Laboratories Ltd. has gained 51.72% in the last 1 Year

Divi's Laboratories Ltd.

03 Feb 2025

5734.50

2.60%

to see Rapid results content

Divi's Laboratories Ltd.

03 Feb 2025

5734.50

2.60%

Custom synthesis drives earnings; generics stable QoQ

Neutral: Divi's Laboratories Ltd.

Target

Motilal Oswal

Divi’s Laboratories (DIVI) delivered in-line revenue. However, it reported better-than-expected EBITDA/PAT led by a better product mix and lower tax rate (due to the shift to a new tax regime).